Skip to main content

CORRECTION article

Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1514836

Corrigendum: Anti-cancer immune effect of human colorectal cancer neoantigen peptide based on MHC class I molecular affinity screening

Provisionally accepted
Siyu Zhang Siyu Zhang 1Changxin Huang Changxin Huang 1*Yongqiang Li Yongqiang Li 1*Zhaoyang Li Zhaoyang Li 1*Ying Zhu Ying Zhu 2*Lili Yang Lili Yang 1*Haokun Hu Haokun Hu 1*Quan Sun Quan Sun 1*Mengmeng Liu Mengmeng Liu 3*Songqiang Cao Songqiang Cao 4
  • 1 Department of Oncology, Affiliated Hospital of Hangzhou Normal University, Hangzhou, China
  • 2 Department of Clinical Hematology and Transfusion, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China
  • 3 Department of Psychiatry and Psychology, 155 Hospital of Kaifeng city, Kaifeng city, China
  • 4 Department of Urology, Huaihe hospital of Henan University, Kaifeng, China

The final, formatted version of the article will be published soon.

    The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated. In the published article, there was an error in the legend for [FIGURE 5] as published. [The percentages of T, B and NK cells in the mixed cells were identified by flow cytometry in control group shows the experimental group after adding peptides. The proportions of CD3+CD4+ double positive (CD4+ T cells), CD3+CD8+ double positive (CD8+ T cells), CD3-CD56 + (NK cells) and CD3-CD19 + (B cells) were 7.8%, 14.63%, 7.81% and 1.40%, respectively.]. The corrected legend appears below.[The percentages of T, B, and NK cells in the mixed cell population were analyzed by flow cytometry in the control group, which did not include the addition of peptides. The proportions of CD3+CD4+ double positive (CD4+ T cells), CD3+CD8+ double positive (CD8+ T cells), CD3-CD56 + (NK cells) and CD3-CD19 + (B cells) were 7.8%, 4.63%, 7.81% and 1.40%, respectively.] The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated. In the published article, there was an error in the Funding statement. In the published article, there were [three] errors. [Results], [1]. This sentence previously stated: "[3. Neoantigen Peptides Promote CD4+, CD8+ T, and NK Cell Proliferation: After 14 days, flow cytometry showed higher percentages of CD4+ T (37.41% vs 7.8%), CD8+ T (16.67% vs 14.63%), and NK cells (33.09% vs 7.81%) in the experimental group, indicating that the neoantigen peptides induced proliferation of CD4+, CD8+ T cells, and NK cells.]"The corrected sentence appears below: "[3. Neoantigen Peptides Promote CD4+, CD8+ T, and NK Cell Proliferation: After 14 days, flow cytometry showed higher percentages of CD4+ T (37.41% vs 7.8%), CD8+ T (16.67% vs 4.63%), and NK cells (33.09% vs 7.81%) in the experimental group, indicating that the neoantigen peptides induced proliferation of CD4+, CD8+ T cells, and NK cells.]"

    Keywords: Tumor immunotherapy, Tumor vaccine, neoantigen, MHC molecular affinity, colorectal cancer

    Received: 21 Oct 2024; Accepted: 20 Nov 2024.

    Copyright: © 2024 Zhang, Huang, Li, Li, Zhu, Yang, Hu, Sun, Liu and Cao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Changxin Huang, Department of Oncology, Affiliated Hospital of Hangzhou Normal University, Hangzhou, China
    Yongqiang Li, Department of Oncology, Affiliated Hospital of Hangzhou Normal University, Hangzhou, China
    Zhaoyang Li, Department of Oncology, Affiliated Hospital of Hangzhou Normal University, Hangzhou, China
    Ying Zhu, Department of Clinical Hematology and Transfusion, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China
    Lili Yang, Department of Oncology, Affiliated Hospital of Hangzhou Normal University, Hangzhou, China
    Haokun Hu, Department of Oncology, Affiliated Hospital of Hangzhou Normal University, Hangzhou, China
    Quan Sun, Department of Oncology, Affiliated Hospital of Hangzhou Normal University, Hangzhou, China
    Mengmeng Liu, Department of Psychiatry and Psychology, 155 Hospital of Kaifeng city, Kaifeng city, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.